Thierry Tidiane Diagana

Thierry Tidiane Diagana

Auto-generated profile, based on publicly available information

Thierry Tidiane Diagana

Novartis Institute for Tropical Diseases, Emeryville, CA, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2010 in Science
Verified
Journal Article
Closed access
PDF file
MRMatthias Rottmann
Matthias Rottmann
CMCase McNamara
Case McNamara
BYBryan K. S. Yeung
Bryan K. S. Yeung
MLMarcus C. S. Lee
Marcus C. S. Lee
BZBin Zou
Bin Zou
TDThierry T. Diagana
Thierry T. Diagana
Antimalarial Drug Candidate: Spiroindolones were discovered as promising antimalarial drug candidates through a high-throughput screening approach that should be applicable to a range of neglected infectious diseases. Rottmann et al. (p. 1175 ; see the Perspective by Wells ) present the preclinical profile for an optimized spiroindolone drug candidate, NITD609. They obtained evidence for a decrease in drug sensitivity in strains of the malaria parasite Plasmodium falciparum bearing amino acid mutations in the P-type ATPase, indicating possible mechanisms of action and/or resistance.

27 November 2013 in Nature
Verified
Journal Article
Open access
PDF file
CMCase W. McNamara
Case W. McNamara
MLMarcus C. S. Lee
Marcus C. S. Lee
CLChek Shik Lim
Chek Shik Lim
SLSiau Hoi Lim
Siau Hoi Lim
JRJason Roland
Jason Roland
EWElizabeth A. Winzeler
Elizabeth A. Winzeler
Achieving the goal of malaria elimination will depend on targeting Plasmodium pathways essential across all life stages. Here we identify a lipid kinase, phosphatidylinositol-4-OH kinase (PI(4)K), as the target of imidazopyrazines, a new antimalarial compound class that inhibits the intracellular development of multiple Plasmodium species at each stage of infection in the vertebrate host. Imidazopyrazines demonstrate potent preventive, therapeutic, and transmission-blocking activity in rodent malaria models, are active against blood-stage field isolates of the major human pathogens P. falciparum and P. vivax, and inhibit liver-stage hypnozoites in the simian parasite P. cynomolgi. We show that imidazopyrazines exert their effect through inhibitory interaction with the ATP-binding pocket of PI(4)K, altering the intracellular distribution of phosphatidylinositol-4-phosphate. Collectively, our data define PI(4)K as a key Plasmodium vulnerability, opening up new avenues of target-based discovery to identify drugs with an ideal activity profile for the prevention, treatment and elimination of malaria.

31 May 2017 in Nature
Verified
Journal Article
Open access
PDF file
UMUjjini H. Manjunatha
Ujjini H. Manjunatha
SVSumiti Vinayak
Sumiti Vinayak
JZJennifer A. Zambriski
Jennifer A. Zambriski
ACAlexander T. Chao
Alexander T. Chao
TSTracy Sy
Tracy Sy
TDThierry T. Diagana
Thierry T. Diagana
Diarrhoeal disease is responsible for 8.6% of global child mortality. Recent epidemiological studies found the protozoan parasite Cryptosporidium to be a leading cause of paediatric diarrhoea, with particularly grave impact on infants and immunocompromised individuals. There is neither a vaccine nor an effective treatment. Here we establish a drug discovery process built on scalable phenotypic assays and mouse models that take advantage of transgenic parasites. Screening a library of compounds with anti-parasitic activity, we identify pyrazolopyridines as inhibitors of Cryptosporidium parvum and Cryptosporidium hominis. Oral treatment with the pyrazolopyridine KDU731 results in a potent reduction in intestinal infection of immunocompromised mice. Treatment also leads to rapid resolution of diarrhoea and dehydration in neonatal calves, a clinical model of cryptosporidiosis that closely resembles human infection. Our results suggest that the Cryptosporidium lipid kinase PI(4)K (phosphatidylinositol-4-OH kinase) is a target for pyrazolopyridines and that KDU731 warrants further preclinical evaluation as a drug candidate for the treatment of cryptosporidiosis.

1 September 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
KKKelli L. Kuhen
Kelli L. Kuhen
ACArnab K. Chatterjee
Arnab K. Chatterjee
MRMatthias Rottmann
Matthias Rottmann
KGKerstin Gagaring
Kerstin Gagaring
RBRachel Borboa
Rachel Borboa
TDThierry T. Diagana
Thierry T. Diagana
Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle. We have previously reported the discovery of a novel class of antimalarial compounds in the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of malaria. Consistent with the previously reported activity profile of this series, the clinical candidate KAF156 shows blood schizonticidal activity with 50% inhibitory concentrations of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99% effective doses of 0.6, 0.9, and 1.4 mg/kg, respectively. When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protective as a single oral dose of 10 mg/kg. Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro and in vivo . Collectively, our data suggest that KAF156, currently under evaluation in clinical trials, has the potential to treat, prevent, and block the transmission of malaria.

7 January 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
UMUjjini H. Manjunatha
Ujjini H. Manjunatha
SRSrinivasa P. S. Rao
Srinivasa P. S. Rao
RKRavinder Reddy Kondreddi
Ravinder Reddy Kondreddi
CNChristian G. Noble
Christian G. Noble
LCLuis R. Camacho
Luis R. Camacho
TDThierry T. Diagana
Thierry T. Diagana
4-Hydroxy-2-pyridones, direct inhibitors of the mycobacterial protein InhA, are active against multidrug-resistant Mycobacterium tuberculosis .

13 December 2018 in ACS Infectious Diseases
Verified
Journal Article
Open access
SRSrinivasa Rao
Srinivasa Rao
MBMichael P. Barrett
Michael P. Barrett
GDGlenn Dranoff
Glenn Dranoff
CFChristopher J. Faraday
Christopher J. Faraday
CGClaudio R. Gimpelewicz
Claudio R. Gimpelewicz
TDThierry T. Diagana
Thierry T. Diagana
Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host–parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.